table 1: list of primers and primer sequences...primer sequence ezh2 forward cgg tgt caa acg cca ata...

Primer SequenceEZH2

Forward CGG TGT CAA ACG CCA ATA AAReverse CCG CTC CAC TCC ACA TTC TC

E-cadherinForward TGA GTG TCC CCC GGT ATC TTCReverse CAG TAT CAG CCG CTT TCA GAT TTT

SETD2Forward CCT GTC TTG GCC TTT CAG AGReverse GTA AGG CAT GGT GAC GGA CT

ALDH1AForward GCA ACT GAG GAG GAG CTC TGReverse AGC TAC CAT AGT ACG CCA CG

HIF2aForward CCC TCC CAG ATG GAG AGT CAReverse TCA CAT TTG GCA AGT GCA GC

E2F1Forward CCG GGG AAT GAA GGT GAA CAReverse GAG CAA AAG GGC GGA AAG TG

N-CadherinForward ACT CCA GGG GAC CTT TTC CTReverse TGG CCC AGT TAC ACG TAT CC

ZEBForward ACG GTA TTG CCA ACC CTC TGReverse TGC ATT CTT CAC TGG ACC ATC

VASH1Forward AAG AGG CCC TGC CAA TCA AAReverse CAC GAT GTG GCG GAA GTA GT

SNAILForward CCG GAA CCG AAA CGT GAC TAReverse TTT CGG TGG GCA GGT AAT CC

GAPDHForward CTC TGC TCC TCC TGT TCG ACReverse GCG CCC AAT ACG ACC AAA TC

AluForward CAG GTG GAT TGG CTT GAG TTReverse CAC GCC CAG CTA ATT TTT GT

Table 1: List of primers and primer sequences

A B

C

Supplemental Figure 1

m1 m2 RP-R-02 RPR02LM

m1 m2

EZH2

β-Actin

E-Cadherin

D

H&E Co

ntro

l Su

nitin

ib

Lungs A

B Control

CD31

/Ki6

7

Sunitinib


mCD31 Ki67

Con

trol

Su

nitin

ib

Axi

tinib

H&E Lungs

Con

trol

Su

nitin

ib

Axi

tinib

A

B C


A B C

B-Actin

E-Cadherin

m1 m2 m3 m1 m2 m3 m1 m2 m3 Control Sunitinib Bevacizumab

RP-R-02LM D


Supplemental Figure 5 A

(Log

2)

-2.6

6 2.

66

B

C

Supplemental Figure 6 UMR-C2R Washed out UMR-C2R Washed out + SunitinibUMR-C2R Chronic

EZH2/F-ACTINEZH2/F-ACTINEZH2/F-ACTIN

UMR-C2R Washed out UMR-C2R Washed out + SunitinibUMR-C2R Chronic

Global Phosphoserine/F-actin/Hoechst Global Phosphoserine/F-actin/Hoechst Global Phosphoserine/F-actin/Hoechst

Global Phosphotyrosine/Hoechst Global Phosphotyrosine/Hoechst Global Phosphotyrosine/Hoechst

Phospho FAK/Hoechst Phospho FAK/Hoechst Phospho FAK/Hoechst



Log2 ratio (Resistant/Sensitive)

-Log

(p-v

alue

)

p < 0.05

429 427

A 786-0

786-0R

B

786-0 786-0R C


VEGF signaling pathway


786-

0 78

6-0R

78

6-0R

shE

ZH2

Control Axitinib Sorafenib (2uM)

Glo

bal s

erin

e ph

osph

oryl

atio

n A

EZH2

β-actin

786-

0Rm

ock

786-

0Rsh

EZH2

786-

0

B


Control Sunitinib

EPZ011989 Combination

EZH

2/pA

KT

E

ZH2/

pAK

T

Control Sunitinib


EZH

2/pF

AK

E

ZH2/

pFA

K

A

B


Control Sunitinib


EC

adhe

rin/

Hoe

chst

EC

adhe

rin/

Hoe

chst

C

-7000 -3500 5’ End 3’ End 3500 7000

786-0 786-0R 786-0R shEZH2 786-0 786-0R

EZH2 H3K27me3

-2 -1 0 2 3

Color Key

log2(Fold-Change)

0 1 2-2 -1

786-

0R78

6-0

786-

0R sh

EZH2

786-

0R

Top GSEA categories786-0R Return to normal

1. ALK Down vs Up2. KRAS.Breast Up vs Up3. KRAS.Prostate Up vs Down4. BCAT Up5. KRAS.Breast Up vs Down6. Apical Surface7. KRAS.Kidney Up vs Up

Top GSEA categoriesRP-R-02LM Return to normal

1. KRAS.Kidney Up vs Up2. WNT Beta Catenin Signaling3. Apical Surface4. PRC2 SUZ12 Up vs Down5. KRAS.Breast Up vs Up

Term P-value Adjusted P-valueSUZ12_NT2-D1_hg19 1.4216E-58 1.16002E-55

EZH2_B cell_hg19 1.12546E-32 4.59188E-30CBX2_K562_hg19 3.18551E-25 8.66458E-23SUZ12_K562_hg19 1.11259E-21 2.26968E-19

EZH2_skeletal muscle myoblast_hg19 5.52973E-17 9.02452E-15CBX8_K562_hg19 7.62524E-15 8.88886E-13

EZH2_keratinocyte_hg19 4.19326E-15 5.70284E-13SUZ12_H1-hESC_hg19 5.872E-12 5.98944E-10

Term P-value Adjusted P-valueSUZ12_K562_hg19 2.48424E-07 0.000202714

SUZ12_NT2-D1_hg19 6.47138E-05 0.013201609CBX2_K562_hg19 6.3426E-05 0.013201609

EZH2_astrocyte_hg19 4.4523E-05 0.013201609EZH2_B cell_hg19 8.97653E-05 0.014649689CBX8_K562_hg19 0.000176294 0.023975954

REST_HCT116_hg19 0.000480614 0.049022671EZH2_keratinocyte_hg19 0.000461804 0.049022671

-7000 -3500 5’ End 3’ End 3500 7000 -7000 -3500 5’ End 3’ End 3500 7000 -7000 -3500 5’ End 3’ End 3500 7000 -7000 -3500 5’ End 3’ End 3500 7000

A

B

C D


A

B


table 1: list of primers and primer sequences...primer sequence ezh2 forward cgg tgt caa acg cca ata...

Documents